

Continuing Education/Continuing Medical Education (CE/CME)

**Congdon Lecture Series 2024 - Addiction: Opioid Use Disorder and Buprenorphine**

WHEN: June 12, 2024 — 10:00 AM

**Presentation purpose:**

* This program is designed to enhance primary care providers' skills in addressing addiction with evidence-based strategies. Topics include Alcohol Use Disorder and its management in primary care, the impact of nutrient deficiencies in use disorders, and effective treatments like Buprenorphine for Opioid Use Disorder (OUD). Explore harm reduction approaches and learn about practical, evidence-based opioid abatement strategies for utilizing settlement funds. Additionally, the conference will cover Tobacco Use Disorder and its treatment. Equip yourself with the knowledge and tools to improve patient care and outcomes in the realm of addiction.

**Learning objectives:**

* 1 Demonstrate proper administration and management protocols for Buprenorphine in treating patients with Opioid Use Disorder.
* 2 Counsel patients and their families on the benefits and potential risks of Buprenorphine treatment, promoting understanding and informed consent.
* 3 Evaluate patients with Opioid Use Disorder to determine their eligibility for Buprenorphine treatment, considering medical history, comorbidities, and substance use patterns.

**Target audience:**

This activity is designed for the interdisciplinary audience including the following:

Specialties: Emergency Medicine, Family Medicine, General Medicine, Primary Care, Internal Medicine

**Accreditation**

In support of improving patient care, Ascension is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Genesys Regional Medical Center (GRMC) is accredited by the American Osteopathic Association to provide osteopathic continuing medical education for physicians.

**Credit designation:**



This activity was planned by and for the healthcare team, and learners will receive 1.00 IPCE credit(s) for learning and change.



Ascension designates this Live Activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



This activity is awarded 1.00 ANCC contact hour(s). (based on 60 minutes per contact hour)









GRMC designates this program for a maximum of 1 AOA Category 1A Credit(s) and will report CME and specialty credits commensurate with the extent of the physician’s participation in this activity.



**Faculty/Course Director/Planners:**

Ascension has selected all faculty participating in this activity. It is the policy of Ascension that all CE/CME planning committees, faculty, authors, editors, and staff disclose relationships with commercial interests upon nomination or invitation of participation. Disclosure documents are reviewed for potential conflicts of interest and if relevant, they are resolved prior to confirmation of participation. Only those participants who have no conflict of interest or who agreed to an identified resolution process prior to their participation were involved in this activity.

**Conflict of Interest:**

In accordance with the ACCME Standards for Commercial Support, it is the policy of Ascension to ensure balance, independence, objectivity and scientific rigor in all CE/CME activities.

Full disclosure of conflicts and conflict resolution will be made in writing via handout materials or syllabus.

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| Ismael D Yanga III, MD | Course Director, Physician Planner | Nothing to disclose - 05/24/2024 |
| Dana Burtrum, MA | Activity Coordinator | Nothing to disclose - 11/17/2023 |
| Adam Shammami, DO | Faculty | Nothing to disclose - 05/28/2024 |
| Gina Dahlem, PhD | Nurse Planner | Nothing to disclose - 05/24/2024 |

**Commercial Support:**

No commercial interest was received for this CE/CME activity.